| Item Type | Name |
|
Concept
|
Antineoplastic Combined Chemotherapy Protocols
|
|
Concept
|
Corneal Diseases
|
|
Concept
|
Cardiovascular Diseases
|
|
Concept
|
Drug Therapy, Combination
|
|
Concept
|
Hematologic Diseases
|
|
Concept
|
Peripheral Nervous System Diseases
|
|
Concept
|
Recurrence
|
|
Concept
|
Hematopoietic Stem Cell Transplantation
|
|
Concept
|
Disease Management
|
|
Concept
|
Stem Cell Transplantation
|
|
Concept
|
Neoplasm Recurrence, Local
|
|
Concept
|
Disease Progression
|
|
Concept
|
Hematopoietic Stem Cell Mobilization
|
|
Concept
|
Secondary Prevention
|
|
Concept
|
Induction Chemotherapy
|
|
Concept
|
Disease Models, Animal
|
|
Concept
|
Neoplastic Stem Cells
|
|
Concept
|
Disease-Free Survival
|
|
Concept
|
Maintenance Chemotherapy
|
|
Academic Article
|
Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma.
|
|
Academic Article
|
Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untreated multiple myeloma: a southwest oncology group trial (S0204).
|
|
Academic Article
|
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
|
|
Academic Article
|
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.
|
|
Academic Article
|
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.
|
|
Academic Article
|
Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study.
|
|
Academic Article
|
An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib.
|
|
Academic Article
|
Clinical roundtable monograph. Emerging treatment options for relapsed and refractory multiple myeloma.
|
|
Academic Article
|
Novel therapies for relapsed/refractory multiple myeloma: how can we improve on "salvage" therapy?--introduction.
|
|
Academic Article
|
Management strategies for relapsed/refractory multiple myeloma: current clinical perspectives.
|
|
Academic Article
|
An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma.
|
|
Academic Article
|
Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial.
|
|
Academic Article
|
Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study.
|
|
Academic Article
|
Superior overall survival of patients with myeloma achieving very good partial response or better to initial treatment with bortezomib, pegylated liposomal doxorubicin, and dexamethasone, predicted after two cycles by a free light chain- and M-protein-based model: extended follow-up of a phase II trial.
|
|
Academic Article
|
Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma.
|
|
Academic Article
|
Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.
|
|
Academic Article
|
Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial.
|
|
Academic Article
|
Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma.
|
|
Academic Article
|
An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma.
|
|
Academic Article
|
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.
|
|
Academic Article
|
Evolving strategies in the initial treatment of multiple myeloma.
|
|
Academic Article
|
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
|
|
Academic Article
|
Introduction: recent advances in the understanding and management of multiple myeloma.
|
|
Academic Article
|
A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.
|
|
Academic Article
|
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.
|
|
Academic Article
|
Current strategies for treatment of relapsed/refractory multiple myeloma.
|
|
Academic Article
|
Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients.
|
|
Academic Article
|
Proteomic profiling of naïve multiple myeloma patient plasma cells identifies pathways associated with favourable response to bortezomib-based treatment regimens.
|
|
Academic Article
|
Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma.
|
|
Academic Article
|
Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study.
|
|
Academic Article
|
Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma.
|
|
Academic Article
|
Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10-Dependent Apoptosis by Carfilzomib and Selinexor.
|
|
Academic Article
|
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.
|
|
Academic Article
|
Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1.
|
|
Academic Article
|
Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM.
|
|
Academic Article
|
Anti-myeloma activity of MELK inhibitor OTS167: effects on drug-resistant myeloma cells and putative myeloma stem cell replenishment of malignant plasma cells.
|
|
Academic Article
|
Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma.
|
|
Academic Article
|
A phase 1 dose-escalation study of filanesib plus bortezomib and dexamethasone in patients with recurrent/refractory multiple myeloma.
|
|
Academic Article
|
Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective.
|
|
Academic Article
|
Comparative proteomic profiling of refractory/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy.
|
|
Academic Article
|
Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma.
|
|
Academic Article
|
Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study.
|
|
Academic Article
|
Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells.
|
|
Academic Article
|
Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment.
|
|
Academic Article
|
Cardiovascular events during carfilzomib therapy for relapsed myeloma: practical management aspects from two case studies.
|
|
Academic Article
|
Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma.
|
|
Academic Article
|
Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States.
|
|
Academic Article
|
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
|
|
Academic Article
|
Comparative proteomic profiling of sera from patients with refractory multiple myeloma reveals potential biomarkers predicting response to bortezomib-based therapy.
|
|
Academic Article
|
Reframing the Value of Treatments for Relapsed/Refractory Multiple Myeloma.
|
|
Academic Article
|
Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
|
|
Academic Article
|
Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study.
|
|
Academic Article
|
Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma.
|
|
Academic Article
|
Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.
|
|
Academic Article
|
Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma.
|
|
Academic Article
|
Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults.
|
|
Academic Article
|
Potent anti-myeloma activity of the TOPK inhibitor OTS514 in pre-clinical models.
|
|
Academic Article
|
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.
|
|
Academic Article
|
Regulatory T-cell depletion in the setting of autologous stem cell transplantation for multiple myeloma: pilot study.
|
|
Academic Article
|
First-in-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma.
|
|
Academic Article
|
Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma.
|
|
Academic Article
|
Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses.
|
|
Academic Article
|
Comparative Efficacy of Bortezomib, Melphalan, and Prednisone (VMP) With or Without Daratumumab Versus VMP Alone in the Treatment of Newly Diagnosed Multiple Myeloma: Propensity Score Matching of ALCYONE and VISTA Phase III Studies.
|
|
Academic Article
|
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.
|
|
Academic Article
|
Clinician attitudes and practices toward measurable residual disease in multiple myeloma.
|
|
Academic Article
|
Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma.
|
|
Academic Article
|
Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysis.
|
|
Academic Article
|
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials.
|
|
Academic Article
|
Recommendations and outcomes from a geriatric assessment guided multidisciplinary clinic prior to autologous stem cell transplant in older patients.
|
|
Academic Article
|
Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation.
|
|
Academic Article
|
Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM).
|
|
Academic Article
|
Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial.
|
|
Academic Article
|
Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE.
|
|
Academic Article
|
Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma.
|
|
Academic Article
|
Knowing the unknowns in high risk multiple myeloma.
|
|
Academic Article
|
Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.
|
|
Academic Article
|
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study.
|
|
Academic Article
|
Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN.
|
|
Academic Article
|
Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma.
|
|
Academic Article
|
Efficacy and safety of carfilzomib-lenalidomide-dexamethasone in newly diagnosed multiple myeloma: pooled analysis of four single-arm studies.
|
|
Academic Article
|
Clinician survey regarding measurable residual disease-guided decision-making in multiple myeloma.
|
|
Academic Article
|
Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study.
|
|
Academic Article
|
Longitudinal Real-World Neuropathy and Patient-Reported Outcomes With Bortezomib and Lenalidomide in Newly Diagnosed Multiple Myeloma.
|
|
Academic Article
|
Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials.
|
|
Academic Article
|
Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial.
|
|
Academic Article
|
Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice.
|
|
Academic Article
|
Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study.
|
|
Academic Article
|
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma.
|
|
Academic Article
|
A phase I study of selinexor combined with weekly carfilzomib and dexamethasone in relapsed/refractory multiple myeloma.
|
|
Academic Article
|
Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma.
|
|
Academic Article
|
A plain language summary of daratumumab plus lenalidomide/bortezomib/dexamethasone in transplant-eligible Black patients with newly diagnosed multiple myeloma in the GRIFFIN study.
|
|
Academic Article
|
Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial.
|
|
Academic Article
|
Measurable residual disease in peripheral blood in myeloma: dream or reality.
|
|
Academic Article
|
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial.
|
|
Academic Article
|
Optimization of Metabolic Tumor Volume as a Prognostic Marker in CAR T-Cell Therapy for Aggressive Large B-cell NHL.
|